特異性：Human Anti-C5 Antibody is a research grade biosimilar of the monoclonal antibody drug eculizumab. It is a recombinant human IgG2/4 kappa antibody with variable regions from the therapeutic antibody eculizumab. Human Anti-C5 Antibody is for research use only. It is suitable as a reference standard in a pharmacokinetic (PK) bridging ELISA with anti-eculizumab antibodies. It can also be used as capture and detection reagent in an anti-drug antibody (ADA) bridging ELISA, with an anti-eculizumab antibody in IgG1 format as reference standard. Eculizumab (Soliris) is a humanized IgG2/4 kappa antibody. The heavy chains are comprised of human IgG2 sequences in CH1, the hinge and the adjacent portion CH2, and human IgG4 sequences in the remaining part of CH2 and CH3. The drug is used to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare acquired life-threatening disease of the blood characterized by destruction of red blood cells by the complement system. It also has approval as an orphan drug for treatment of atypical hemolytic uremic syndrome (aHUS). Eculizumab specifically binds to the terminal complement component 5 (C5) and inhibits the cleavage of C5 to C5a and C5b by the C5 convertase, which prevents the generation of the terminal complement complex C5b-9. Both C5a and C5b-9 cause the terminal complement-mediated events that are characteristic of PNH and aHUS. A 1:1 molar ratio of eculizumab to C5 is sufficient for C5 inhibition.
純度：>98% by SDS PAGE
形状：Purified; Human IgG2/4 (kappa) antibody - liquid
